A Population-based Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 564,760
- 试验地点
- 1
- 主要终点
- congenital malformations
研究概览
简要总结
The DEEP cohort is the first population-based cohort of pregnant population in China that longitudinally documents drug uses throughout the pregnancy life course and adverse pregnancy outcomes.
详细描述
The DEEP cohort is the first population-based cohort of pregnant population in China that longitudinally documents drug uses throughout the pregnancy life course and adverse pregnancy outcomes. The main goal of the study aims to monitor and evaluate the safety of drug use through the pregnancy life course in the Chinese setting. The DEEP cohort is developed primarily based on the population-based data platforms in Xiamen, a municipal city of 5 million population in southeast China. Based on these data platforms, a pregnancy-centered registry was developed that documented health care services and outcomes in the maternal and other departments. For identifying drug uses, a drug prescription database was specifically developed by using electronic healthcare records documented in the platforms across the primary, secondary and tertiary hospitals. By linking the pregnancy registry and prescription database through a unique identifier, the DEEP cohort was developed. All the pregnant women and their offspring in Xiamen are provided with health care and followed up according to standard protocols in the region, including antenatal care, delivery care, postpartum follow-up and childhood follow-ups. The primary adverse outcomes - congenital malformations - are collected using a standardized Case Report Form.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 14 Years 至 65 Years(Child, Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pregnant women who registered at the Maternal and Child Health Management Platform in Xiamen.
排除标准
- 未提供
研究组 & 干预措施
drug exposure
chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs
干预措施: chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs (Drug)
结局指标
主要结局
congenital malformations
时间窗: up to 42 days after delivery
Number of births with congenital malformations
次要结局
- preterm birth(up to 37 gestational weeks)
- low birth weight(Immediately after delivery)
研究者
Sun Xin
Director of Chinese Evidence-based Medicine Center
West China Hospital
